T1	intervention 0 10	Gabapentin
T2	total-participants 30 33	420
T4	total-participants 372 375	420
T3	eligibility 376 448	women with breast cancer who were having two or more hot flashes per day
T6	control 472 479	placebo
T8	total-participants 815 818	371
T9	control-participants 844 847	119
T10	intervention-participants 857 860	123
T11	intervention-participants 884 887	129
T12	total-participants 911 914	347
T13	control-participants 927 930	113
T14	intervention-participants 940 943	114
T15	intervention-participants 967 970	120
T16	outcome 1019 1043	hot-flash severity score
T17	cv-bin-percent 1099 1102	21%
T18	cv-bin-percent 1125 1128	15%
T19	iv-bin-percent 1161 1164	33%
T20	outcome 1065 1078	weeks 4 and 8
T21	iv-bin-percent 1180 1183	31%
T22	iv-bin-percent 1240 1243	49%
T23	iv-bin-percent 1259 1262	46%
T5	condition 15 26	hot flashes
T7	outcome 1562 1594	hot-flash frequency and severity
